TG Therapeutics, Inc. Aktie News

TG Therapeutics beat first quarter revenue expectations and raised the full-year revenue guidance by $40 million at the mid-point. Work on the subcutaneous version of Briumvi continues and could represent the next step for increased long-term growth expectations. TG plans to start another clinical trial of Briumvi in a second autoimmune disease and the trial of azer-cel is on track to start thi...

Bolstered by sales of its one commercialized product, the biotech's revenue rose sharply in the first quarter. TG Therapeutics missed on the bottom line, but investors were more cheered by the top-line development.

TG Therapeutics, Inc. (NASDAQ:TGTX ) Q1 2024 Earnings Conference Call May 1, 2024 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - President and Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Conference Call Participants Michael DiFiore - Evercore ISI Edward White - H.C. W...

TG Therapeutics Inc is up 30% on Wednesday even though it reported a wider-than-expected per-share loss for its fiscal first quarter. Why is TG Therapeutics stock up today?

First quarter 2024 BRIUMVI U.S. net revenue of $50.5 million, representing >25% quarter over quarter growth

Conference call to be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET Conference call to be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado. Links to the data presented...

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® (ublituximab-xiiy) to be the preferred agent listed on the VA National Formulary for Anti-CD20 Antibody indications for patients with relapsing forms of multiple sclerosis (RMS).